GlassScriptPhysician profile
David B La Vine
NPI 1962635763
$3,705.39
in general payments reported to CMS, 2019-2025
27 companies · $689 in 2025
The $689 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,144 · 2020: $69.57 · 2021: $51.75 · 2022: $257 · 2023: $616 · 2024: $877 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,180 · Travel and Lodging: $1.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,180.47 |
| Travel and Lodging | $1.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $575.15 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $543.92 | 2019-2025 | Repatha, Evenity, Otezla |
| Lilly USA, LLC | $399.55 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $354.82 | 2019-2025 | |
| Glaxosmithkline, LLC. | $295.86 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Astrazeneca Pharmaceuticals LP | $204.71 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $175.59 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Takeda Pharmaceuticals U.S.A., INC. | $135.38 | 2019 | |
| Bridgebio Pharma, INC. | $128.47 | 2025 | Attruby |
| Daiichi Sankyo INC. | $121.22 | 2019-2025 | Injectafer |
| Teva Pharmaceuticals USA, INC. | $112.08 | 2019 | |
| Janssen Pharmaceuticals, INC | $106.47 | 2019 | |
| Novartis Pharmaceuticals Corporation | $91.32 | 2024 | |
| Boston Scientific Corporation | $87.85 | 2019 | |
| Astellas Pharma US INC | $45.73 | 2024 | Veozah |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $44.48 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $43.49 | 2024 | Voquezna |
| Exact Sciences Corporation | $38.51 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $34.71 | 2019-2020 | |
| Inspire Medical Systems, INC. | $32.94 | 2024 | Inspire |
| Medtronic, INC. | $22.32 | 2025 | Symplicity G3 |
| Actelion Pharmaceuticals US, INC. | $21.24 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.81 | 2024 | |
| Eisai INC. | $20.65 | 2023 | |
| Phadia US INC. | $16.87 | 2024 | Immunocap |
| Antares Pharma, INC. | $16.28 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.97 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David La Vine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.